Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Wu

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Nature Genetics|August 2, 2019
Mapping cis-regulatory chromatin contacts in neural cells links neuropsychiatric disorder risk variants to target genesMichael Song, Xiaoyu Yang, Xingjie Ren, et al.
Blood|September 24, 2024
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINEJennifer R Brown, Barbara Eichhorst, Nicole Lamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Neoadjuvant Enzalutamide Prior to ProstatectomyBruce Montgomery, Maria S Tretiakova, Anthony M Joshua, et al.
Clinical and Translational Medicine|January 24, 2025
Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancerSally E Claridge, Shalini Nath, Anneliese Baum, et al.
Future Oncology (London, England)|December 13, 2023
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
The New England Journal of Medicine|December 13, 2022
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Future Oncology (London, England)|August 12, 2024
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Nature Genetics|September 6, 2005
Identification of mutations in CUL7 in 3-M syndromeCéline Huber, Dora Dias-Santagata, Anna Glaser, et al.
The Journal of Experimental Medicine|August 17, 2005
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in miceAnne Hermanowski-Vosatka, James M Balkovec, Kang Cheng, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Nature Genetics|August 2, 2019
Mapping cis-regulatory chromatin contacts in neural cells links neuropsychiatric disorder risk variants to target genesMichael Song, Xiaoyu Yang, Xingjie Ren, et al.
Blood|September 24, 2024
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINEJennifer R Brown, Barbara Eichhorst, Nicole Lamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Neoadjuvant Enzalutamide Prior to ProstatectomyBruce Montgomery, Maria S Tretiakova, Anthony M Joshua, et al.
Clinical and Translational Medicine|January 24, 2025
Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancerSally E Claridge, Shalini Nath, Anneliese Baum, et al.
Future Oncology (London, England)|December 13, 2023
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
The New England Journal of Medicine|December 13, 2022
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Future Oncology (London, England)|August 12, 2024
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Nature Genetics|September 6, 2005
Identification of mutations in CUL7 in 3-M syndromeCéline Huber, Dora Dias-Santagata, Anna Glaser, et al.
The Journal of Experimental Medicine|August 17, 2005
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in miceAnne Hermanowski-Vosatka, James M Balkovec, Kang Cheng, et al.
Pageof 9